A5000827518- Virus-based gene therapy research
- Cancer Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Pancreatic and Hepatic Oncology Research
- Sarcoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Phagocytosis and Immune Regulation
- CRISPR and Genetic Engineering
- Neuroblastoma Research and Treatments
- RNA Interference and Gene Delivery
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Garlic and Onion Studies
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacogenetics and Drug Metabolism
- Intracerebral and Subarachnoid Hemorrhage Research
- Drug Transport and Resistance Mechanisms
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- Head and Neck Cancer Studies
- Poisoning and overdose treatments
- Parvovirus B19 Infection Studies
- Lung Cancer Treatments and Mutations
University Hospital Heidelberg
2012-2023
Heidelberg University
2010-2023
Heidelberg (Poland)
2010
University Hospital of Zurich
2010
Universitäts-Herzzentrum Freiburg-Bad Krozingen
2002
Abstract Background The treatment of patients with malignant brain tumors remains a major oncological problem. median survival glioblastoma multiforme (GBM), the most type, is only 15 months after initial diagnosis and even less tumor recurrence. Improvements standard including surgery radio-chemotherapy have not lead to improvements. Therefore, alternative therapeutics such as oncolytic viruses that specifically target destroy cancer cells are under investigation. Preclinical data...
Metastatic pancreatic cancer has a dismal prognosis, with mean six-month progression-free survival of approximately 50% and median about 11 months. Despite intensive research, only slight improvements clinical outcome could be achieved over the last decades. Hence, new innovative therapeutic strategies are urgently required. ParvOryx is drug product containing native parvovirus H-1 (H-1PV). Since H-1PV was shown to exert pronounced anti-neoplastic effects in pre-clinical models cancer,...
Abstract Purpose: To investigate the safety, clinical efficacy, virus pharmacokinetics, shedding, and immune response after administration of an oncolytic parvovirus (H-1PV, ParvOryx) to patients with metastatic pancreatic ductal adenocarcinoma (PDAC) refractory first-line therapy. Patients Methods: This is a noncontrolled, single-arm, open-label, dose-escalating, single-center trial. Seven PDAC at least one liver metastasis were included. ParvOryx was administered intravenously on 4...
The disposition of nortildine, the active metabolite synthetic opioid drug tilidine, was investigated in healthy volunteers a randomized, single‐dose, three‐way crossover design. Three different treatments were administered: tilidine 50 mg intravenously, orally, and nortilidine 10 intravenously. plasma concentrations nortilidine, bisnortilidine determined subjected to pharmacokinetic analysis using noncompartmental methods. systemic bioavailability low (7.6% ± 5.3%) due pronounced first‐pass...
BACKGROUND: Among various experimental therapies for glioblastoma is the use of oncolytic viruses that specifically target and destroy cancer cells. Parvovirus H-1 (H-1PV), an apathogenic rodent DNA virus, tested in a phase 1/2a trial patients with recurrent (ParvOryx01 trial, clinical identifier NCT01301430). Here we report on series 6 previously treated ParvOryx01 who received at another recurrence additional local dose H-1PV based compassionate (CU) agreement. METHODS: (all male, age 51...
Imexon [AOP99.0001 (4-imino-1,3-diazobicyclo[3. 1. 0]-hexan-2-one)] belongs to a novel class of promising anticancer agents that induce tumor apoptosis through oxidative stress. Clinical experience since the late 1960s has provided initial evidence for clinical antitumor activity. Our open-label, multicenter phase I trial was designed further investigate adverse event (AEs) profile and pharmacokinetics AOP99.0001 in pretreated myeloma patients collect data on potential efficacy this...
Abstract Background Primary treatment of carcinoma the oro-/hypopharynx or larynx may consist combined platinum-containing chemoradiotherapy. In order to improve clinical outcome (i.e. local control/overall survival), therapy is intensified by addition EGFR inhibitor cetuximab (Erbitux ® ). Radiation (RT) carried out as intensity-modulated RT (IMRT) avoid higher grade acute and late toxicity sparing surrounding normal tissues. Methods/Design The REACH study a prospective phase II combining...
A promising alternative strategy for the treatment of glioblastoma multiforme (GBM) is use oncolytic viruses (OVs) that specifically replicate in and destroy tumor cells. In addition to direct oncolysis, OVs offer chance induction anti-tumor immune effects can be combined with standard therapies. Parvovirus H-1 (H-1PV) a small single-stranded DNA virus rodent origin anti-glioma properties rat models. Intratumoral intravenous infection led cure orthotopic gliomas while at same time raising an...
Abstract Expression of CYP3A5 protein is a basal and acquired resistance mechanism pancreatic ductal adenocarcinoma cells conferring protection against the CYP3A CYP2C8 substrate paclitaxel through metabolic degradation. Inhibition isozymes restores sensitivity to paclitaxel. The combination gemcitabine nab‐paclitaxel an established regimen for treatment metastasized or locally advanced inoperable cancer. Cobicistat inhibitor developed pharmacoenhancement protease inhibitors. addition...
TPS2111 Background: The management of glioblastoma multiforme (GBM) is an unsolved problem and medium survival has remained at dismal 15 months. Among alternative treatments the use oncolytic viruses which preferentially kill tumor cells. Preclinical work using rat glioma models showed that rodent parvovirus H-1PV was able to cure gliomas after single intratumoral or multiple intravenous injections (K. Geletneky et al. Neuro-Oncology 2010), forming basis for a clinical trial with H-1PV....